Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELUNASDAQ:GLSINYSE:IKTNASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELUCelularity$2.35-1.3%$1.76$1.00▼$5.22$56.28M0.61333,558 shs16,532 shsGLSIGreenwich LifeSciences$9.72-2.6%$9.70$8.06▼$18.75$129.94M1.7446,385 shs39,235 shsIKTInhibikase Therapeutics$2.04+15.3%$2.03$1.12▼$4.20$151.66M1.01234,957 shs168,057 shsLYELLyell Immunopharma$0.41-0.1%$0.45$0.39▼$2.80$121.09M-0.251.03 million shs298,991 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELUCelularity-1.26%+11.90%+50.26%+92.62%-30.27%GLSIGreenwich LifeSciences-2.61%-0.10%-3.19%-15.77%-26.31%IKTInhibikase Therapeutics+15.25%+3.55%-7.27%-12.82%+15.91%LYELLyell Immunopharma-0.15%0.00%-7.03%-42.48%-85.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELUCelularity0.1567 of 5 stars0.01.00.00.01.71.70.0GLSIGreenwich LifeSciences2.0266 of 5 stars3.50.00.00.03.33.30.0IKTInhibikase Therapeutics1.4062 of 5 stars3.30.00.00.02.10.00.6LYELLyell Immunopharma2.2424 of 5 stars2.80.00.00.02.15.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELUCelularity 0.00N/AN/AN/AGLSIGreenwich LifeSciences 3.00Buy$39.00301.23% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50218.63% UpsideLYELLyell Immunopharma 1.50Reduce$1.00143.90% UpsideCurrent Analyst Ratings BreakdownLatest CELU, LYEL, GLSI, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/13/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELUCelularity$54.22M1.04$9.79 per share0.24$2.11 per share1.11GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/AIKTInhibikase Therapeutics$260K583.30N/AN/A$1.78 per share1.15LYELLyell Immunopharma$65K1,862.90N/AN/A$2.60 per share0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELUCelularity-$196.29M-$2.65N/A∞N/A-72.72%-119.53%-25.40%7/28/2025 (Estimated)GLSIGreenwich LifeSciences-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ALYELLyell Immunopharma-$234.63M-$1.25N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)Latest CELU, LYEL, GLSI, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/13/2025Q1 2025LYELLyell Immunopharma-$0.19-$0.18+$0.01-$0.18N/A$0.01 million5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELUCelularityN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELUCelularityN/A0.190.14GLSIGreenwich LifeSciencesN/A6.916.91IKTInhibikase TherapeuticsN/A0.850.85LYELLyell ImmunopharmaN/A13.4313.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELUCelularity19.02%GLSIGreenwich LifeSciences4.16%IKTInhibikase Therapeutics3.81%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipCELUCelularity22.10%GLSIGreenwich LifeSciences51.67%IKTInhibikase Therapeutics7.30%LYELLyell Immunopharma25.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELUCelularity22023.95 million18.55 millionOptionableGLSIGreenwich LifeSciences313.37 million6.35 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableCELU, LYEL, GLSI, and IKT HeadlinesRecent News About These CompaniesvenBio Partners LLC Makes New Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 22, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Acquires New Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 19, 2025 | marketbeat.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 17, 2025 | finanznachrichten.deOrbimed Advisors LLC Decreases Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 15, 2025 | marketbeat.comLyell Immunopharma Advances CAR T-Cell Therapy PipelineMay 14, 2025 | tipranks.comLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025May 13, 2025 | globenewswire.comForesite Capital Management V LLC Invests $5.21 Million in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 12, 2025 | marketbeat.comAlmitas Capital LLC Takes Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 4, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL)May 3, 2025 | marketbeat.comLyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025May 1, 2025 | globenewswire.comLyell Immunopharma (LYEL) Projected to Post Earnings on MondayApril 30, 2025 | marketbeat.comLyell Immunopharma announces FDA granted RMAT designation to LYL314April 17, 2025 | markets.businessinsider.comWhy Lyell Immunopharma, Inc.’s (LYEL) Stock Is Up 7.22%April 16, 2025 | aaii.comLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaApril 15, 2025 | globenewswire.comCAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisitionApril 8, 2025 | fiercepharma.comLyell Cuts 73 Employees as Part of LA Site ClosureApril 7, 2025 | biospace.comOtis W. Brawley Buys 35,640 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockApril 3, 2025 | insidertrades.comBank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)March 28, 2025 | markets.businessinsider.comIs Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comWhy Lyell Immunopharma, Inc.’s (LYEL) Stock Is Up 20.28%March 20, 2025 | aaii.comFavourable Signals For Lyell Immunopharma: Numerous Insiders Acquired StockMarch 20, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, LYEL, GLSI, and IKT Company DescriptionsCelularity NASDAQ:CELU$2.35 -0.03 (-1.26%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$2.33 -0.02 (-0.85%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Greenwich LifeSciences NASDAQ:GLSI$9.72 -0.26 (-2.61%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$9.34 -0.38 (-3.90%) As of 05/28/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Inhibikase Therapeutics NYSE:IKT$2.04 +0.27 (+15.25%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$2.04 +0.00 (+0.25%) As of 05/28/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Lyell Immunopharma NASDAQ:LYEL$0.41 0.00 (-0.15%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.42 +0.01 (+1.46%) As of 05/28/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
